Pluri Inc. (Pluristem Therapeutics Inc.) 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on December 17, 2013, by Pluristem Therapeutics Inc., a Nevada corporation. The report details the execution of investment agreements related to a strategic partnership previously announced in June 2013.
Key Financial Metrics and Transaction Details
The filing reports a specific transaction rather than periodic financial statements. Key metrics include:
- Total Consideration: $10.4 million.
- Pluristem Shares Issued: 2,500,000 shares of common stock issued to CHA Bio&Diostech ("CHA").
- Implied Share Price: $4.16 per common share.
- CHA Shares Received: 1,011,504 common shares of CHA issued to Pluristem.
- Liquidity Impact: The filing does not provide updated cash flow, debt, or liquidity figures beyond the transaction details.
Material Changes and Transaction Structure
This filing represents the closing of the investment component of the exclusive out-license and strategic partnership agreement between Pluristem Ltd. (a wholly owned subsidiary) and CHA. Both parties issued shares to one another, and all shares issued in this transaction are subject to a one-year lock-up period.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, management commentary on future performance, or specific risk factors beyond the standard lock-up restrictions on the newly issued shares. The transaction is presented as a fulfillment of the prior agreement.
Investor Verification Checklist
- Verify the current market price of Pluristem shares relative to the $4.16 transaction price.
- Confirm the status of the one-year lock-up period for the 2,500,000 shares issued to CHA.
- Review the June 27, 2013 Form 8-K for the full terms of the underlying strategic partnership and out-license agreement.
- Assess the valuation and liquidity of the 1,011,504 CHA shares received by Pluristem.